Vidac Pharma's VDA-1275 Shows Promising Efficacy Across Solid Tumor Models and Enhances Standard Treatments

19 February 2024 | Monday | News

Preclinical Studies Highlight Potential Breakthrough in Cancer Therapy with Synergistic Effects and Immunomodulatory Properties
Image Source | Public Domain

Image Source | Public Domain

Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed promising outcomes for its novel drug candidate, VDA-1275. The drug exhibited substantial efficacy in various mouse cancer models and human cellular organoid models of solid tumors. Furthermore, VDA-1275 displayed synergistic effects when combined with standard-of-care cancer treatments, sorafenib and cisplatin. These findings will be presented at the Sachs 17th Annual European Life Sciences CEO Forum on February 28.

Max Herzberg, CEO of Vidac Pharma, expressed enthusiasm over the robust results of VDA-1275, emphasizing its potential to revolutionize cancer treatment. Herzberg stated, "VDA-1275 demonstrates remarkable potency in inhibiting cancer cell proliferation and inducing apoptosis. The significant synergistic effects observed in combination with established cancer drugs offer promise for enhancing treatment outcomes while minimizing chemotherapy-related side effects."

In preclinical trials, VDA-1275 showcased statistically significant survival benefits in murine models of colorectal cancer, comparable to Opdivo in head-to-head comparisons. Additionally, both human and murine 2D and 3D cell culture models exhibited improved survival rates across lung, prostate, and colon cancer types. Notably, in a 3-D organoid model of human liver cancer, VDA-1275 substantially reduced the concentrations of sorafenib and cisplatin required for cancer cell viability.

Furthermore, VDA-1275 triggered an immune response by promoting anti-tumor M1 macrophages while inhibiting tumor-promoting M2 macrophages. It also facilitated a shift of mouse CD8+ effector T-cells to memory cells without compromising T-cell survival. Vidac Pharma plans to publish these results in a peer-reviewed publication.

Both VDA-1275 and the more advanced VDA-1102 disrupt the interaction between hexokinase 2 (HK2) and voltage-dependent anion channels (VDACs) in mitochondria, a mechanism vital for cancer cell metabolism and survival. Clinical data from Vidac's first-generation metabolic checkpoint modulators have demonstrated significant efficacy in halting cancer cell proliferation and restoring immune sensitivity and apoptosis.

The promising results of VDA-1275 mark a significant advancement in Vidac Pharma's mission to develop innovative cancer therapies, with the potential to reshape the landscape of cancer treatment paradigms.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close